Journals / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 5

Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat

Pages
1434–1435
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

ÇELEBİER, M., HAZNEDAROĞLU, İ. C. (2022). Antiinfective and wound-healing pleiotropic actions of Ankaferd hemostat. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 5, 1434–1435. https://ajindex.com/articles/609731

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Mehmet G, Günay A, Tanık A. An evaluation of the effects of caffeic acid phenethyl ester and Ankaferd blood stopper on secondary wound healing of oral mucosal tissue. Turkish Journal of Medical Sciences 2020
  2. 50(1): 248-257. doi: 10.3906/ sag-1908-114 2. Erçetin S, Haznedaroğlu İC, Mevlüt K, Önal İK, Aktaş A et al. Safety and efficacy of Ankaferd Blood Stopper in dental surgery. International Journal of Hematology and Oncology 2010
  3. 28(4): 1-5. 3. Haznedaroğlu BZ, Beyazıt Y, Walker SL, Haznedaroğlu İC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Critical Reviews in Oncology/Hematology 2012
  4. 83(1): 21-34. doi: 10.1016/j.critrevonc.2011.10.006 4. Patıroğlu T, Şahin NE, Ünal E, Kendirci M, Karakükçü M et al. Effectiveness of Ankaferd BloodStopper in prophylaxis and treatment of oral mucositis in childhood cancers evaluated with plasma citrulline levels. Turkish Journal of Hematology 2018
  5. 35(1): 75-93. doi: 10.4274/tjh.2017.0320 5. Atay MH, Arslan NA, Aktimur S, Büyükkaya P, Kelkitli E et al. Safety and efficacy of ankaferd hemostat (ABS) in the chemotherapy-induced oral mucositis. International Journal of Hematology and Oncology 2015
  6. 28(4): 166-171. https://doi. org/10.4999/uhod.15811 6. Chopra A, Sivaraman K. Ankaferd blood stopper: A novel hemostatic agent with unique antimicrobial, antineoplastic and regenerative properties. Journal of Research in Pharmacy 2019
  7. 23(5): 777-784. doi: 10.35333/jrp.2019.24 7. Luo L, Jin Y, Kim ID, Lee JK. Glycyrrhizin suppresses HMGB1 inductions in the hippocampus and subsequent accumulation in serum of a kainic acid-induced seizure mouse model. Cellular and Molecular Neurobiology 2014
  8. 34(7): 987-997. doi: 10.1007/s10571-014-0075-4 8. Smolarczyk R, Cichoń T, Matuszczak S, Mitrus I, Lesiak M et al. The role of Glycyrrhizin, an inhibitor of HMGB1 protein, in anticancer therapy. Archivum Immunologiae et Therapiae Experimentalis 2012
  9. 60(5): 391-399. doi:10.1007/s00005-012- 0183-0 9. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H et al. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003
  10. 361(9374): 2045-2046. 10. Chen G, Chen D, Li J, Czura CJ, Tracey KJ et al. Pathogenic role of HMGB1 in SARS? Medical Hypotheses 2004
  11. 63(4): 691-695. 11. Kim SW, Jin Y, Shin JH, Kim ID, Lee HK et al. Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylatio